The Institute’s Appraisal Committee analysed data supplied by Alimera but raised concerns over a number of uncertainties.
Sir Andrew Dillon, NICE Chief Executive, said the information supplied did not show the benefits to patients to “justify the price the NHS is being asked to pay.”
Alimera Sciences submitted additional information following draft guidance, which was published by NICE in August.
But the updated data failed to impress NICE’s Appraisal Committee who questioned the implant’s clinical effectiveness, its negative side effects and how Alimera had judged Iluvien’s use in current clinical practice.
“When NICE recommends any drug or treatment, we have to be sure that it is both clinically and cost effective, because money has to be diverted from elsewhere in the health service to pay for it,” said Sir Andrew Dillon.